Immediate risk of suicide and cardiovascular death after a prostate cancer diagnosis

Feb 02, 2010

Being diagnosed with prostate cancer may increase a man's risk of suicide or cardiovascular death, especially right after diagnosis, according to a new study published online February 2 in the Journal of the National Cancer Institute.

To study the risks men diagnosed with in the United States face, Fang Fang, M.D., of the Channing Laboratory, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, in Boston, and colleagues used data from over 340,000 prostate cancer patients listed in the Surveillance, Epidemiology, and End Results database between 1979 and 2004 and from the general population. The researchers compared risks in the first year and months after diagnosis.

According to the study, 148 men died of suicide (mortality rate = 0.5 per 1,000 person-years) and 6,845 died of cardiovascular diseases (mortality rate = 21.8 per 1000 person-years). Increased risk of suicide was found during the first year, in particular the first 3 months. The risk of cardiovascular death was slightly elevated during the first year, especially in the first month and particularly among those with metastatic disease.

According to the study, the elevated was apparent before prostate-specific antigen (PSA) testing was common (1979) and when it was first introduced (1987), but not since PSA testing has been widespread (1993). The authors say this observation is most likely due to the potentially lower degree of stress associated with the diagnosis of indolent prostate cancer.

"We believe that suicide and cardiovascular death reflect only the tip of the iceberg of anxiety, mood disturbance, and perhaps other mental illness (or suffering) after a prostate cancer diagnosis," the authors write. "Hence, our study suggests the potential importance of providing emotional counseling and support for patients newly diagnosed with cancer. It also adds to the increasingly complex scenario of pros and cons of extensive PSA testing, which entails detection of large numbers of nonlethal prostate cancers."

Explore further: Lung cancer test less effective in areas where infectious lung disease is more common

More information: jnci.oxfordjournals.org

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

XenOPAT, mouse models for personalized cancer treatment

9 hours ago

On September 8th, the company XenOPAT SL, a spin-off of the Institute of Biomedical Research (IDIBELL) and the Catalan Institute of Oncology (ICO) was established with the aim of bringing the company the latest scientific ...

User comments : 0